Juno Therapeutics June 15th Short Interest Update

Juno Therapeutics (NASDAQ:JUNO) reported a rise of 8.7% or 697,465 shares in its short interest. The short figure came in at 12.2% of the total floats. The average daily volume of 1,541,572 shares suggests that the days to cover 8,719,636 short positions, as on June 15,2016, will be 6. On May 31,2016, the short interest was 8,022,171 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Juno Therapeutics (NASDAQ:JUNO): The stock opened at $41.20 on Friday but the bulls could not build on the opening and the stock topped out at $42.98 for the day. The stock traded down to $40.00 during the day, due to lack of any buying support eventually closed down at $40.45 with a loss of -7.44% for the day. The stock had closed at $43.70 on the previous day. The total traded volume was 5,451,308 shares.

The company shares have dropped -12.64% from its 1 Year high price. On Jun 30, 2015, the shares registered one year high at $59.60 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $41.62 and the 200 Day Moving Average price is recorded at $39.12.

Juno Therapeutics (NASDAQ:JUNO) has tumbled 4.6% during the past week and has dropped 3.78% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 3.02%. Juno Therapeutics (NASDAQ:JUNO) has underperformed the index by 0.87% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *